Infinimmune’s immunology focus shows up again through its preclinical and early-stage program set, with IL-22-directed biology positioned for inflammatory disease areas such as atopic dermatitis. The Merck collaboration specifically describes its targets as intended to improve on safety and efficacy for existing therapies. While no clinical endpoints are reported in the Merck deal itself, the companies’ stated biology tie into immunomodulatory pipelines where IL-22 and IL-13 pathways are already validated by prior clinical successes in related conditions. For biotech teams, this cluster matters because it links platform discovery deals directly to cytokine targets under active development across multiple programs.